Synthetic gene network restoring endogenous pituitary-thyroid feedback control in experimental Graves' disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 5, 2016, Pages 1244-1249

  Saxena, Pratik ^a   Hamri, Ghislaine Charpin El ^b   Folcher, Marc ^a   Zulewski, Henryk ^a,c,e   Fussenegger, Martin ^a,d  

^a ETH ZURICH   (Switzerland)

^b Institut Universitaire de Technologie   (France)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Cell engineering; Designer cells; Gene switch; Prosthetic networks; Synthetic biology

Indexed keywords

AUTOANTIBODY; HORMONE ANTAGONIST; SYNTHETIC DNA; THYROID HORMONE; THYROID HORMONE RECEPTOR ALPHA; THYROID STIMULATING HORMONE RECEPTOR ANTAGONIST; THYROTROPIN; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE EXPRESSION; GRAVES DISEASE; HOMEOSTASIS; HYPERTHYROIDISM; HYPOPHYSIS THYROID SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TSH SECRETING CELL; ANIMAL; BLOOD; CELL CULTURE; DISEASE MODEL; GENE REGULATORY NETWORK; GENETICS; HUMAN; HYPOPHYSIS; PATHOPHYSIOLOGY; THYROID GLAND; VALIDATION STUDY;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEEDBACK; GENE REGULATORY NETWORKS; GENES, SYNTHETIC; GRAVES DISEASE; HUMANS; MICE; PITUITARY GLAND; THYROID GLAND; THYROID HORMONES;

EID: 84956702282     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1514383113     Document Type: Article

References (44)

1. Mullur R, Liu YY, Brent GA (2014) Thyroid hormone regulation of metabolism. Physiol Rev 94(2):355-382.
2. Abdalla SM, Bianco AC (2014) Defending plasma T3 is a biological priority. Clin Endocrinol (Oxf) 81(5):633-641.
3. Zoeller RT, Tan SW, Tyl RW (2007) General background on the hypothalamic-pituitarythyroid (HPT) axis. Crit Rev Toxicol 37(1-2):11-53.
4. Wu Y, Koenig RJ (2000) Gene regulation by thyroid hormone. Trends Endocrinol Metab 11(6):207-211.
5. Brabant G, et al. (1990) Circadian and pulsatile TSH secretion under physiological and pathophysiological conditions. Horm Metab Res Suppl 23:12-17.
6. Prummel MF, Brokken LJ, Wiersinga WM (2004) Ultra short-loop feedback control of thyrotropin secretion. Thyroid 14(10):825-829.
7. Franklyn JA (1994) The management of hyperthyroidism. N Engl J Med 330(24):1731-1738.
8. Cooper DS (2003) Hyperthyroidism. Lancet 362(9382):459-468.
9. Bahn RS (2010) Graves' ophthalmopathy. N Engl J Med 362(8):726-738.
10. Bartalena L (2013) Diagnosis and management of Graves disease: A global overview. Nat Rev Endocrinol 9(12):724-734.
11. Brent GA (2008) Clinical practice. Graves' disease. N Engl J Med 358(24):2594-2605.
12. Cooper DS (2005) Antithyroid drugs. N Engl J Med 352(9):905-917.
13. Ross DS (2011) Radioiodine therapy for hyperthyroidism. N Engl J Med 364(6):542-550.
14. Bahn RS (2012) Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev Clin Pharmacol 5(6):605-607.
15. Davies TF, Latif R (2015) Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies. Expert Opin Ther Targets 19(6):835-847.
16. Emerson CH (2011) When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use? Thyroid 21(8):817-819.
17. Bartalena L (2013) Graves' orbitopathy: Imperfect treatments for a rare disease. Eur Thyroid J 2(4):259-269.
18. Azzam N, Bar-Shalom R, Kraiem Z, Fares F (2005) Human thyrotropin (TSH) variants designed by site-directed mutagenesis block TSH activity in vitro and in vivo. Endocrinology 146(6):2845-2850.
19. Brent GA (2012) Mechanisms of thyroid hormone action. J Clin Invest 122(9):3035-3043.
20. Potter CJ, Tasic B, Russler EV, Liang L, Luo L (2010) The Q system: A repressible binary system for transgene expression, lineage tracing, and mosaic analysis. Cell 141(3):536-548.
21. Schroeder A, Jimenez R, Young B, Privalsky ML (2014) The ability of thyroid hormone receptors to sense t4 as an agonist depends on receptor isoform and on cellular cofactors. Mol Endocrinol 28(5):745-757.
22. Grøntved L, et al. (2015) Transcriptional activation by the thyroid hormone receptor through ligand-dependent receptor recruitment and chromatin remodelling. Nat Commun 6:7048.
23. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR (2005) Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115(9):2524-2533.
24. Buettner C, Harney JW, Larsen PR (1998) The 3'-untranslated region of human type 2 iodothyronine deiodinase mRNA contains a functional selenocysteine insertion sequence element. J Biol Chem 273(50):33374-33378.
25. Fares FA, Levi F, Reznick AZ, Kraiem Z (2001) Engineering a potential antagonist of human thyrotropin and thyroid-stimulating antibody. J Biol Chem 276(7):4543-4548.
26. Chazenbalk GD, Kakinuma A, Jaume JC, McLachlan SM, Rapoport B (1996) Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells. Endocrinology 137(11):4586-4591.
27. Mueller S, et al. (2009) The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor. J Biol Chem 284(24):16317-16324.
28. Sanders J, et al. (2003) Human monoclonal thyroid stimulating autoantibody. Lancet 362(9378):126-128.
29. East-Palmer J, Szkudlinski MW, Lee J, Thotakura NR, Weintraub BD (1995) A novel, nonradioactive in vivo bioassay of thyrotropin (TSH). Thyroid 5(1):55-59.
30. Neumann S, et al. (2014) A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinology 155(1):310-314.
31. Hamidi S, Aliesky H, Chen CR, Rapoport B, McLachlan SM (2010) Variable suppression of serum thyroxine in female mice of different inbred strains by triiodothyronine administered in drinking water. Thyroid 20(10):1157-1162.
32. Jacobs-Tulleneers-Thevissen D, et al.; Beta Cell Therapy Consortium EU-FP7(2013) Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 56(7):1605-1614.
33. Ausländer S, Ausländer D, Müller M, Wieland M, Fussenegger M (2012) Programmable single-cell mammalian biocomputers. Nature 487(7405):123-127.
34. Ausländer S, et al. (2014) A general design strategy for protein-responsive riboswitches in mammalian cells. Nat Methods 11(11):1154-1160.
35. Folcher M, et al. (2014) Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. Nat Commun 5:5392.
36. Rössger K, Charpin-El-Hamri G, Fussenegger M (2013) A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat Commun 4:2825.
37. Ye H, et al. (2013) Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci USA 110(1):141-146.
38. Kim T, Folcher M, Doaud-El Baba M, Fussenegger M (2015) A synthetic erectile optogenetic stimulator enabling blue-light-inducible penile erection. Angew Chem Int Ed Engl 54(20):5933-5938.
39. Nevozhay D, Zal T, Balázsi G (2013) Transferring a synthetic gene circuit from yeast to mammalian cells. Nat Commun 4:1451.
40. Ausländer D, et al. (2014) A designer cell-based histamine-specific human allergy profiler. Nat Commun 5:4408.
41. Weber W, et al. (2003) Streptomyces-derived quorum-sensing systems engineered for adjustable transgene expression in mammalian cells and mice. Nucleic Acids Res 31(14):e71.
42. Fussenegger M, Mazur X, Bailey JE (1997) A novel cytostatic process enhances the productivity of Chinese hamster ovary cells. Biotechnol Bioeng 55(6):927-939.
43. Kemmer C, et al. (2010) Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat Biotechnol 28(4):355-360.
44. Simonsen JL, et al. (2002) Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 20(6):592-596.